PMID: 14506546Sep 25, 2003

Cardioprotection by Carvedilol: antiapoptosis is independent of beta-adrenoceptor blockage in the rat heart

Journal of Cardiovascular Pharmacology and Therapeutics
Ernst R SchwarzPeter Hanrath


Carvedilol, a beta-blocking agent with beta-blocking properties is now widely used for the treatment of congestive heart failure. In addition to its beta-adrenergic receptor blockage, antiapoptotic effects have been demonstrated in experimental animals. The cardioprotective effects of carvedilol and its hydroxylated analogue BM-91.0228 were tested with regard to their infarct-limiting and antiapoptotic properties in an experimental infarct model in the rat heart. Anesthetized rats were subjected to either 30 (groups 1 to 3) or 60 minutes (groups 4 to 6) of coronary artery occlusion followed by 30 minutes of reperfusion. Groups 1 and 4 served as the control; groups 2 and 5 received intravenous Carvedilol (1 mg/kg) and groups 3 and 6 received intravenous administration of BM-91.0228 (1 mg/kg), respectively, 5 minutes prior to coronary occlusion. Infarct sizes were measured by triphenyltetrazolium chloride staining. In situ visualization of apoptosis was measured by nick end labeling. Carvedilol reduced infarct size after 30 minutes of coronary occlusion compared to controls (8.7% +/- 2.7% versus 27.3% +/- 3.4%, P <.001), while BM-91.0228 showed no significant infarct size reduction (23.7% +/- 5.9%, NS). Neither Carvedilol (36.9% ...Continue Reading


Jan 11, 1992·Journal of Cardiovascular Pharmacology·G Z FeuersteinR R Ruffolo
Jan 1, 1993·Transactions of the American Clinical and Climatological Association·T N James
Sep 1, 1996·Journal of Cardiovascular Pharmacology·H BrunvandK Grong
Jul 13, 2000·Journal of Cardiovascular Pharmacology·T KurzG Richardt
Feb 20, 2002·JAMA : the Journal of the American Medical Association·JoAnne Micale FoodyHarlan M Krumholz


Jun 29, 2012·The Journal of Pharmacology and Experimental Therapeutics·Fatemat HassanMahmood Khan
Feb 28, 2006·Circulation Journal : Official Journal of the Japanese Circulation Society·Ryosuke KametaniMasunori Matsuzaki
Sep 12, 2009·European Journal of Pharmacology·Chunyu DengShuguang Lin
Dec 31, 2016·Biomolecules & Therapeutics·Zuzana BolognaIl-Man Kim
May 18, 2004·The American Journal of Cardiology·Brian Dulin, William T Abraham
Oct 26, 2005·Biophysical Chemistry·Stephanie ButlerCynthia S Randall
Jul 3, 2008·Journal of Cardiovascular Pharmacology and Therapeutics·Maria J CrespoNelson Escobales
Oct 8, 2005·Journal of Cardiovascular Pharmacology and Therapeutics·Ernst R SchwarzJutta Schaper
Jul 17, 2009·Journal of Cardiovascular Pharmacology and Therapeutics·Ernst R SchwarzJustin E Fuess
Apr 24, 2004·American Journal of Physiology. Heart and Circulatory Physiology·Keisuke KawaiChang-seng Liang
Dec 19, 2009·Scandinavian Journal of Immunology·H LiuL Chen
Dec 2, 2005·Journal of Investigative Surgery : the Official Journal of the Academy of Surgical Research·Fernando Lopez-NeblinaLuis H Toledo-Pereyra

Related Concepts

Adrenergic beta-Antagonists
Myocardial Infarction
Myocardial Reperfusion

Related Feeds


Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Adrenergic Receptors: Trafficking

Adrenergic receptor trafficking is an active physiological process where adrenergic receptors are relocated from one region of the cell to another or from one type of cell to another. Discover the latest research on adrenergic receptor trafficking here.

Related Papers

Journal of the American College of Surgeons
Hongzhe LiMichael J Mann
European Journal of Pharmacology
Pedro MonteiroLuís A Providência
Journal of Nuclear Cardiology : Official Publication of the American Society of Nuclear Cardiology
Nikant Kumar Sabharwal, Avijit Lahiri
© 2021 Meta ULC. All rights reserved